Methods of predicting response of a neoplasm to an EGFR inhibitor and detecting interactions between EGFR and an EGFR regulatory protein

US8329421B2 · kind B2 · utility

Assignee

• Ventana Medical Systems, Inc. · US

Inventors

• William Cameron Powell · San Antonio, US
• Linda Willoughby Kivi · Marana, US
• Patrick Roche · Tullow, IE
• Gary Gooch · Tucson, US
• Fabien Gaire · Starnberg, DE

Key dates

• Filing date: Jul 11, 2008
• Grant date: Dec 11, 2012
• Expiry date: Aug 11, 2028

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2800/52
• WIPO field: Measurement
• WIPO sector: Instruments

Abstract

Disclosed herein are antigen-binding molecules, such as antibodies, that specifically recognize a portion of the EGFR C-terminal (intracellular) regulatory domain that interacts with one or more regulatory molecules (such as Suppressor of Cytokine Signaling (“SOCS”) proteins). In certain normal or neoplastic cells and/or tissues, this region is inaccessible to the disclosed antigen-binding molecules. Thus, such antigen-binding molecules are useful at least to interrogate the regulated state of EGFR, predict the response of a cancer patient to EGFR inhibitor therapies, and/or predict the aggressiveness of neoplasms.